Efinaconazole - Bausch Health Companies/Kaken Pharmaceutical

Drug Profile

Efinaconazole - Bausch Health Companies/Kaken Pharmaceutical

Alternative Names: Clenafin; IDP-108; Jublia; KP-103

Latest Information Update: 09 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kaken Pharmaceutical
  • Developer Bausch Health Companies; Dong-A ST; Kaken Pharmaceutical; Tai Tien Pharmaceuticals
  • Class Antifungals; Piperidines; Small molecules; Triazoles
  • Mechanism of Action 14-alpha demethylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Onychomycosis

Most Recent Events

  • 02 Oct 2018 Efinaconazole market licensed to Main Life Corporation in Hong Kong and Macau
  • 02 Oct 2018 Main Life Corporation intends to launch Efinaconazole in Hong Kong and Macau in 2020
  • 21 Sep 2018 Valeant Pharmaceuticals and Kaken Pharmaceuticals initiates litigation against Perrigo over ANDA submission in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top